Cephalexin Susceptibility to Escherichia coli
Cephalexin is active against most wild-type E. coli strains and is FDA-approved for treating genitourinary tract infections caused by susceptible E. coli, but resistance mechanisms—particularly ESBL production and OmpF porin downregulation—significantly limit its clinical utility in contemporary practice. 1
FDA-Approved Activity and Microbiological Data
The FDA label explicitly lists Escherichia coli among organisms against which cephalexin has demonstrated activity both in vitro and in clinical infections, specifically for genitourinary tract infections. 1
Cephalexin achieves very high urinary concentrations (approximately 1000 mcg/mL following a 250 mg dose), which exceed typical MICs for susceptible E. coli strains. 1
Historical studies from the 1970s demonstrated that cephalexin maintained adequate urinary concentrations for treating E. coli urinary tract infections even in patients with impaired renal function. 2
Critical Resistance Mechanisms
ESBL-Producing E. coli
ESBL-producing E. coli demonstrate uniform resistance to all cephalosporins, including first-generation agents like cephalexin, despite the fact that some isolates may test "susceptible" by older breakpoint criteria. 3
ESBL production is now the predominant mechanism of β-lactam resistance among nosocomial E. coli isolates, and ESBL-encoding plasmids frequently co-carry resistance determinants for multiple drug classes. 3
Carbapenems remain the most reliable therapeutic option for infections caused by ESBL-producing E. coli, as these isolates retain carbapenem susceptibility. 3
Non-β-Lactamase Mediated Resistance
OmpF porin disruption or downregulation represents a major cause of cephalexin resistance in E. coli that is not mediated by acquired β-lactamases. This mechanism has been identified in large numbers of isolates from both human infections and cattle. 4
Multiple regulatory mutations cause OmpF downregulation, including rseA mutation (which activates sigma E and increases DegP production, degrading OmpF) and mutations affecting lipopolysaccharide structure. 4
Remarkably, evidence for DegP-mediated OmpF downregulation and gmhB and rseA loss-of-function mutations has been found in E. coli isolates from human infections, indicating this is a clinically relevant resistance mechanism. 4
Susceptibility Testing Limitations
Cephalothin, traditionally used as a class predictor for first-generation cephalosporins, is not a reliable predictor of cephalexin susceptibility in E. coli. Research demonstrates that cephalothin overestimates resistance when tested by automated systems, and neither cephalothin nor cefazolin performs adequately as a surrogate marker. 5
Laboratories should consider testing and reporting cephalexin independently according to clinical need, rather than relying on cephalothin as a class representative. 5
Clinical Context and Comparative Activity
Among first-generation cephalosporins tested against E. coli, the relative potency in decreasing order is cefazolin > cephaloridine > cephalexin > cephalothin, indicating cephalexin is among the less potent agents in its class. 6
Low-dose cephalexin prophylaxis (250 mg nightly) for recurrent urinary tract infections maintained effectiveness without inducing resistance in rectal and vaginal E. coli flora over 6 months of observation. 7
Practical Recommendations
For empiric treatment of E. coli infections:
Use cephalexin only for uncomplicated urinary tract infections in settings with low ESBL prevalence and when local susceptibility data support its use.
Avoid cephalexin in patients with risk factors for ESBL-producing organisms: recent antibiotic exposure (particularly β-lactams or fluoroquinolones within 90 days), healthcare-associated infections, known ESBL colonization, or hospitalization exceeding 5 days. 3, 8
Request specific cephalexin susceptibility testing rather than relying on cephalothin results as a class predictor. 5
For serious infections or when ESBL risk factors are present, empiric carbapenems are preferred, with de-escalation to narrower agents only after susceptibility confirmation. 3